Condition
Heart Failure With Midrange Ejection Fraction
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 3 (1)
Trial Status
Completed1
Terminated1
Not Yet Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04727073Phase 3TerminatedPrimary
Spironolactone in the Treatment of Heart Failure
NCT05789147Not ApplicableCompleted
Transcutaneous Vagus Nerve Stimulation in Heart Failure
NCT06355388Not ApplicableNot Yet Recruiting
TRAnscutaneous vaGUS Nerve Stimulation in Patients With Chronic Heart Failure
Showing all 3 trials